ALZNNasdaqPharmaceutical PreparationsFiscal year ends April 30
Alzamend Neuro, Inc.
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 10, 2026
$1.33+0.03 (+2.31%)
Close on Oct 19, 2026
- Market cap
- $5.96M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.89 (−40.09%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jul 31, 2026
Valuation
- Market cap
- $5.96M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.03
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$9.10M
- EPS, diluted
- -$2.28
- Book value per share
- $1.30
- Diluted shares
- 4M
Eight years at a glance
Fiscal years 2019 to 2026 and trailing twelve months, USD
Operating income
-$9.09M
Net income
-$9.10M
EPS, diluted
-$2.28
Reported periodTrailing twelve months